Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022:52:195-212.
doi: 10.1007/7854_2020_182.

GABAB Receptors and Alcohol Use Disorders: Clinical Studies

Warren B Logge  1   2 , Kirsten C Morley  3 , Paul S Haber  3   4
Affiliations
Review

GABAB Receptors and Alcohol Use Disorders: Clinical Studies

Warren B Logge et al. Curr Top Behav Neurosci. 2022.

Abstract

Harmful alcohol use and alcohol use disorders (AUD) result in major health and community burden worldwide, yet treatment options are limited. Novel pharmacotherapies are urgently required, and treatments involving GABAB receptors have been used in treating alcohol-related disorders. This chapter will review the clinical evidence of GABAB pharmacotherapies, such as baclofen and γ-hydroxybutyric acid. This includes the use of these treatments in individuals experiencing alcohol withdrawal symptoms and outlining the outcomes of studies of alcohol relapse prevention relapse including case studies, comparative studies and randomised controlled trials. Laboratory research investigating biobehavioural effects of baclofen will also be summarised and polymorphisms associated with baclofen treatment, and safety concerns of GABAB treatments will be addressed. In summary, pharmacological treatments targeting GABAB receptors such as baclofen may be modestly effective in the management of alcohol use disorder, but safety concerns limit the widespread applicability of the currently available agents.

Keywords: Alcohol use disorder; Alcohol withdrawal; Baclofen; Neuroimaging; Pharmacotherapy; Psychophysiology; Randomised controlled trial; Treatment.

PubMed Disclaimer

References

    1. Adams CL, Lawrence AJ (2007) CGP7930: a positive allosteric modulator of the GABAB receptor. CNS Drug Rev 13:308–316 - PubMed - PMC
    1. Addolorato G, Caputo F, Capristo E et al (2002a) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37:504–508 - PubMed
    1. Addolorato G, Caputo F, Capristo E et al (2002b) Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 112:226–229 - PubMed
    1. Addolorato G, Leggio L, Abenavoli L et al (2003) Suppression of alcohol delirium tremens by baclofen administration: a case report. Clin Neuropharmacol 26:258 - PubMed
    1. Addolorato G, Leggio L, Abenavoli L et al (2006) Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 119:276.e13–276.e18

LinkOut - more resources